GSK (GSK) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
9 Nov, 2026R&D strategy
Reverse translation starts with human disease questions and early clinical plans, using causal confidence to select mechanisms and patient populations.
Target selection is linked early to phase II proof of concept; biomarker-defined responder groups can replace prolonged empirical biology work.
Complex chronic diseases, including COPD, MASH, pulmonary hypertension and CKD, are viewed as heterogeneous and often driven by systemic, multimorbid risk.
COPD and IL-33
COPD affects 400 million people globally and is the third-biggest killer; targeted therapy remains early, with two approved biologics for the disease.
The portfolio aims to match therapies to distinct COPD risk subtypes; IL-33 is being studied in non-CF bronchiectasis, a mucus-plugging disease without a typical Th2 profile.
COPD phase III starts for IL-33 are planned for next year, following regulatory discussions; phase II non-CF bronchiectasis data are expected by the end of next year.
A planned cardiopulmonary outcomes study will test IL-33’s potential beyond exacerbation reduction, reflecting the link between COPD exacerbations and cardiovascular risk.
DPP-1 inhibition has shown 19%-20% annualized exacerbation reduction in non-CF bronchiectasis; IL-33 may address mucus plugging and patients without Th2 disease.
Long-acting airway therapies
Exdensur SWIFT data showed over 50% annualized exacerbation reduction in asthma, rising to 80%-90% in some more purely uncontrolled populations.
Ultra-long-acting dosing is intended to improve persistence and sustained benefit; remission in asthma may require patients to remain on therapy long enough.
Felcorekibart’s phase II asthma data supported six pivotal PERSIST studies across asthma, nasal polyps and COPD, accelerating starts by nine months; data are expected next year.
Felcorekibart is being advanced at a unified airway dose for twice-yearly administration; the COPD core study was negative, while an eosinophil subgroup informed continued evaluation.
Latest events from GSK
- GBP 1.9bn savings and 22 Phase III starts fuel a >GBP 40bn 2031 sales ambition.GSK
J.P. Morgan UK Leaders Conference - Four- and six-month HIV regimens, pipeline launches and oncology aim to sustain growth through expiries.GSK
Jefferies Global Healthcare Conference - Specialty-led growth and pipeline investment support reaffirmed FY26 guidance.GSK
Q3 2026 - Oncology data highlighted gains across ADCs, immunotherapy and targeted therapies.GSK
ESMO 2026 Investor Briefing - 14% CER sales growth and upgraded outlooks to >£38bn sales by 2031.GSK
Q4 2023 - Ultra-long-acting biologics, AI-driven R&D, and global partnerships are shaping future growth.GSK
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - GBP 1.9bn in savings will fund pipeline growth, with oncology and specialty assets prioritized.GSK
Bank of America Global Healthcare Conference - Rapid portfolio growth and robust clinical data position oncology for major advances by 2031.GSK
Morgan Stanley 24th Annual Global Healthcare Conference - Accelerated R&D, pipeline reinvestment, and specialty focus drive growth and margin stability.GSK
Bernstein’s 23rd Annual Pan-European Strategic Decisions Conference